Form 4: Edgewise Therapeutics Executive John R. Moore Executes Stock Option and Sells Shares
SEC Form 4
John R. Moore, General Counsel of Edgewise Therapeutics, exercised stock options and sold shares of common stock on September 20 and 23, 2024.
Summary
- John R. Moore, the General Counsel of Edgewise Therapeutics, executed stock options to purchase 50,000 shares on September 20, 2024, and 20,922 shares on September 23, 2024, at a price of $0.71 per share.
- On the same days, Moore sold 50,000 shares at $28.3702 and 20,922 shares at $27.6295.
- Following these transactions, Moore directly owns 3,252 shares of common stock.
- Moore also holds options to purchase 62,558 and 41,636 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 09/01/2021 | 1/4th of the shares subject to the option became vested and exercisable |
| 09/20/2024 | John R. Moore exercised options for 50,000 shares at $0.71 and sold 50,000 shares at $28.3702. |
| 09/23/2024 | John R. Moore exercised options for 20,922 shares at $0.71 and sold 20,922 shares at $27.6295. |
| 09/24/2024 | Date of signature for the SEC Form 4 filing. |
| 09/01/2030 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.